Funding for this research was provided by:
Merck & Co., Inc., Kenilworth, NJ, USA
AstraZeneca UK Limited
Received: 26 November 2021
Accepted: 21 February 2022
First Online: 11 March 2022
: Data collection was undertaken in line with the European Pharmaceutical Marketing Research Association guidelines [CitationRef removed]. The questionnaires used in the Prostate Cancer DSP were reviewed and given exemption by the Western Institutional Review Board (reference number: 1-1261035-1). The survey was performed in full accordance with relevant legislation at the time of data collection, including the US Health Insurance Portability and Accountability Act 1996 and the Health Information Technology for Economic and Clinical Health Act legislation [CitationRef removed, CitationRef removed]. Data were collected according to market research guidelines; hence, no source validation was possible or required. Data were collected in such a way that patients and physicians could not be identified directly; all data were aggregated, de-identified and anonymized before receipt by Adelphi Real World and therefore informed consent from individual patients was not required.
: Not applicable.
: JK and SRG are employed by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA and hold stock in Merck & Co., Inc., Kenilworth, NJ, USA. Lingfeng Yang was a previous employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and holds stock in Merck & Co., Inc., Kenilworth, NJ, USA. Lingfeng Yang is an employee of Janssen Global Services, LLC, Horsham, PA, USA. AL, AR, EC, and LG-A are employed by Adelphi Real World and declare no additional competing interests.